Praxis Precision Medicines Touts Encouraging Data For Mid-Stage Epilepsy Drug

Praxis Precision Medicines Touts Encouraging Data For Mid-Stage Epilepsy Drug

Praxis Precision Medicines Inc. announced positive results from its Phase 2 study on relutrigine for SCN2A and SCN8A developmental and epileptic encephalopathy patients, showing a 46% reduction in motor seizures.

Read More

Did you find this insightful?